Dabigatran: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: In medicine, '''dabigatran''' is an anticoagulant that is a direct thrombin inhibitor<ref>{{MeSH}}</ref> In 2009, dabigatran, a direct thrombin inhibitors, was compare...) |
imported>Meg Taylor (subpages) |
||
| Line 1: | Line 1: | ||
{{subpages}} | |||
In [[medicine]], '''dabigatran''' is an [[anticoagulant]] that is a direct [[thrombin]] inhibitor<ref>{{MeSH}}</ref> | In [[medicine]], '''dabigatran''' is an [[anticoagulant]] that is a direct [[thrombin]] inhibitor<ref>{{MeSH}}</ref> | ||
Revision as of 06:30, 30 September 2009
In medicine, dabigatran is an anticoagulant that is a direct thrombin inhibitor[1]
In 2009, dabigatran, a direct thrombin inhibitors, was compared to warfarin in the RE-LY randomized controlled trial.[2]
| Intervention | Outcomes | ||
|---|---|---|---|
| Stroke or systemic embolism | Major bleeding | Mortality | |
| Dabigatran 110 mg twice daily | 1.53% | 2.71%† | 3.75% |
| Dabigatran 150 mg twice daily | 1.11%† | 3.11% | 3.64% |
| Warfarin | 1.69% | 3.36% | 4.13% |
| † p < 0.05 as compared to warfarin group | |||
References
- ↑ Anonymous (2024), Dabigatran (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ 2.0 2.1 Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. (2009). "Dabigatran versus Warfarin in Patients with Atrial Fibrillation.". N Engl J Med 361 (12): 1139-1151. DOI:10.1056/NEJMoa0905561. PMID 19717844. Research Blogging.